Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2013, Pages 672-676

  Dillingh, M R ^a   van den Blink, B ^c   Moerland, M ^a   van Dongen, M G J ^a   Levi, M ^a   Kleinjan, A ^c   Wijsenbeek, M S ^c   Lupher, M L ^b   Harper, D M ^b   Getsy, J A ^b   Hoogsteden, H C ^c   Burggraaf, J ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b Promedior Inc   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Fibrocyte; First in human clinical trial; Macrophage; Pentraxin 2; PRM 151; Pulmonary fibrosis; Serum amyloid P

Indexed keywords

ANTIFIBROTIC AGENT; CD45 ANTIGEN; PLACEBO; PRM 151; PROCOLLAGEN; PROCOLLAGEN 1; SERUM AMYLOID P; UNCLASSIFIED DRUG;

ADULT; AGED; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD PRESSURE; CASE REPORT; CELL POPULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROCYTE; HEART RATE; HUMAN; LUNG ALVEOLUS CELL; LUNG FIBROSIS; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TASTE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADVERSE EVENTS; AE; ELISA; ENZYME LINKED IMMUNOASSAY; ERS/ATS; EUROPEAN RESPIRATORY SOCIETY/AMERICAN THORACIC SOCIETY; FACS; FIBROCYTE; FIH; FIRST-IN-HUMAN CLINICAL TRIAL; FIRT-IN-HUMAN; FLUORESCENCE ACTIVATED CELL SORTER; IDIOPATHIC INTERSTITIAL PNEUMONIA; IDIOPATHIC PULMONARY FIBROSIS; IIP; IL-1; INTERLEUKIN-1; IPF; LIPOPOLYSACCHARIDE; LPS; MACROPHAGE; MCP-1; MONOCYTE CHEMOATTRACTANT PROTEIN-1; PBMC; PD; PDGF; PENTRAXIN-2; PERIPHERAL BLOOD MONONUCLEAR CELL; PF; PHARMACODYNAMICS; PHARMACOKINETICS; PK; PLATELET DERIVED GROWTH FACTOR; PRM-151; PTX-2; PULMONARY FIBROSIS; SAP; SERUM AMYLOID P; SERUM AMYLOID-P; TGF-Β; TNF-Α; TRANSFORMING GROWTH FACTOR-Β; TUMOR NECROSIS FACTOR-Α;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF-LIFE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RECOMBINANT PROTEINS; SERUM AMYLOID P-COMPONENT; YOUNG ADULT;

EID: 84887996436     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.01.008     Document Type: Article

References (24)

1. Swigris J.J., Stewart A.L., Gould M.K., Wilson S.R. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005, 3:61.
2. Nathan S.D., Shlobin O.A., Weir N., Ahmad S., Kaldjob J.M., Battle E., et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011 Jul, 140(1):221-229.
3. King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet 2011 Dec 3, 378(9807):1949-1961.
4. Adkins J.M., Collard H.R. Idiopathic pulmonary fibrosis. Semin Respir Crit Care Med 2012 Oct, 33(5):433-439.
5. Kelly M., Kolb M., Bonniaud P., Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003, 9(1):39-49.
6. Zhang K., Phan S.H. Cytokines and pulmonary fibrosis. Biol Signals 1996 Jul, 5(4):232-239.
7. Gauldie J., Jordana M., Cox G. Cytokines and pulmonary fibrosis. Thorax 1993 Sep, 48(9):931-935.
8. Mehrad B., Burdick M.D., Zisman D.A., Keane M.P., Belperio J.A., Strieter R.M. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007 Feb 2, 353(1):104-108.
9. Phillips R.J., Burdick M.D., Hong K., Lutz M.A., Murray L.A., Xue Y.Y., et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. JClin Invest 2004 Aug, 114(3):438-446.
10. van den Blink B., Wijsenbeek M.S., Hoogsteden H.C. Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2010 Dec, 23(6):515-520.
11. Moeller A., Gilpin S.E., Ask K., Cox G., Cook D., Gauldie J., et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009 Apr 1, 179(7):588-594.
12. Keeley E.C., Mehrad B., Strieter R.M. The role of fibrocytes in fibrotic diseases of the lungs and heart. Fibrogenesis Tissue Repair 2011, 4:2.
13. Pilling D., Gomer R.H. Regulatory pathways for fibrocyte differentiation. Fibrocytes: new insights into tissue repair and systemic fibroses 2007, 37-60. World Scientific Publishing Co. Pte. Ltd. R. Bucala (Ed.).
14. Pilling D., Buckley C.D., Salmon M., Gomer R.H. Inhibition of fibrocyte differentiation by serum amyloid P. JImmunol 2003 Nov 15, 171(10):5537-5546.
15. Pilling D., Roife D., Wang M., Ronkainen S.D., Crawford J.R., Travis E.L., et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. JImmunol 2007 Sep 15, 179(6):4035-4044.
16. Moreira A.P., Cavassani K.A., Hullinger R., Rosada R.S., Fong D.J., Murray L., et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. JAllergy Clin Immunol 2010 Oct, 126(4):712-721.
17. Naik-Mathuria B., Pilling D., Crawford J.R., Gay A.N., Smith C.W., Gomer R.H., et al. Serum amyloid P inhibits dermal wound healing. Wound Repair Regen 2008 Mar, 16(2):266-273.
18. Haudek S.B., Xia Y., Huebener P., Lee J.M., Carlson S., Crawford J.R., et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006 Nov 28, 103(48):18284-18289.
19. Murray L.A., Chen Q., Kramer M.S., Hesson D.P., Argentieri R.L., Peng X., et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int J Biochem Cell Biol 2011 Jan, 43(1):154-162.
20. Murray L.A., Rosada R., Moreira A.P., Joshi A., Kramer M.S., Hesson D.P., et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010, 5(3):e9683.
21. Murray L.A., Kramer M.S., Hesson D.P., Watkins B.A., Fey E.G., Argentieri R.L., et al. Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair 2010, 3:11.
22. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011 Mar 15, 183(6):788-824.
23. Nelson S.R., Tennent G.A., Sethi D., Gower P.E., Ballardie F.W., Amatayakul-Chantler S., et al. Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta 1991 Aug 30, 200(2-3):191-199.
24. Maharjan A.S., Pilling D., Gomer R.H. Toll-like receptor 2 agonists inhibit human fibrocyte differentiation. Fibrogenesis Tissue Repair 2010, 3:23.